• Must be at least 18 years of age.

• An ECOG performance status of ≤ 2.

• Life expectancy of ≥ 9 months.

• Able to eat and digest food normally. Patients with colostomies are allowed.

• Must meet the following:

∙ Newly diagnosed metastatic colorectal adenocarcinoma and about to start first line chemotherapy.

‣ Determined by the Investigator to be ready to receive their second dose of chemotherapy.

• Starting chemotherapy routines allowed are: FOLFOX, FOLFIRI, or FOLFIRINOX with or without bevacizumab, or other monoclonals or other FDA approved agents to be dosed every 2 weeks. The primary cancer therapy (dose, schedule, or drugs) may be changed as medically indicated.

• Must have a BMI ≤ 29 kg/m\^2.

• Must be able and willing to safely self-inject daily or be injected by a caregiver.

• Must have measurable disease by RECIST 1.1 criteria.

⁃ Must have adequate end organ function as defined by:

• ANC ≥ 1.5 × 10\^9/L

∙ Platelets ≥ 100 × 10\^9/L, or adequate as determined by the medical judgement of the investigator

∙ Hemoglobin ≥ 9 g/dL, or adequate as determined by the medical judgement of the investigator

∙ AST and ALT ≤ 3 × ULN; if liver metastases, then ≤ 5 ×ULN

∙ Bilirubin ≤ 1.5 × ULN or ≤ 3 × ULN in the presence of documented Gilbert's Syndrome

∙ Albumin between 3.4 and 5.4 gm/dL or within institutional normal limits, or not considered clinically significant by the investigator

∙ Creatinine clearance ≥ 50 mL/min (calculated by Cockcroft and Gault equation

∙ Normal hemoglobin A1c levels based on institutional normal limits, or not considered clinically significant by the investigator

⁃ NT-Pro-BNP and Troponin (TnI or TnT) are within normal limits or not considered to be clinically significant by the investigator.

⁃ If a female of childbearing capability, must have a negative pregnancy test within 2 weeks of starting treatment.

⁃ Fertile men and women must agree to use adequate contraception for the duration of the trial.

⁃ Willing and able to sign informed consent.